(19)
(11) EP 2 652 511 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
28.06.2017 Bulletin 2017/26

(45) Mention of the grant of the patent:
05.04.2017 Bulletin 2017/14

(21) Application number: 11804867.7

(22) Date of filing: 14.12.2011
(51) International Patent Classification (IPC): 
G01N 33/569(2006.01)
G01N 33/84(2006.01)
 G01N 33/68(2006.01)
G01N 33/537(2006.01)
(86) International application number:
PCT/US2011/064938
(87) International publication number:
WO 2012/082914 (21.06.2012 Gazette 2012/25)

(54)

FLOW CYTOMETRY ANALYSIS OF MATERIALS ADSORBED TO METAL SALTS

DURCHFLUSSZYTOMETRISCHE ANALAYSE VON METALLSALZADSORBIERTEN STOFFEN

ANALYSE DE CYTOMÉTRIE EN FLUX DE MATÉRIAU ADSORBÉ À DES SELS MÉTALLIQUES

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 14.12.2010 US 423001 P

(43) Date of publication of application:
23.10.2013 Bulletin 2013/43

(73) Proprietor: GlaxoSmithKline Biologicals SA
1330 Rixensart (BE)

(72) Inventors:
  • SKIBINSKI, David
    Emeryville, CA 94662-8097 (US)
  • LAERA, Donatello
    I-53100 Siena (IT)
  • NUTI, Sandra
    I-53100 Siena (IT)
  • UGOZZOLI, Mildred
    Emeryville, CA 94662-8097 (US)

(74) Representative: Courgeon, Antoine 
GlaxoSmithKline Global Patents CN925.1 980 Great West Road
Brentford, Middlesex TW8 9GS
Brentford, Middlesex TW8 9GS (GB)


(56) References cited: : 
WO-A1-2007/122373
   
  • MOREFIELD G L ET AL: "Distribution of adsorbed antigen in mono-valent and combination vaccines", VACCINE, ELSEVIER LTD, GB, vol. 22, no. 15-16, 7 May 2004 (2004-05-07), pages 1973-1984, XP004505522, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2003.10.040
  • MILDRED UGOZZOLI ET AL: "Flow cytometry: An alternative method for direct quantification of antigens adsorbed to aluminum hydroxide adjuvant", ANALYTICAL BIOCHEMISTRY, vol. 418, no. 2, 1 November 2011 (2011-11-01), pages 224-230, XP55020095, ISSN: 0003-2697, DOI: 10.1016/j.ab.2011.07.012
  • Xuxin Lai ET AL: "Determination of Adsorbed Protein Concentration in Aluminum Hydroxide Suspensions by Near-Infrared Transmittance Spectroscopy", Applied Spectroscopy, vol. 62, no. 7, 1 July 2008 (2008-07-01), pages 784-790, XP055112767, ISSN: 0003-7028, DOI: 10.1366/000370208784909481
  • KATZ J B ET AL: "IN VITRO ASSESSMENT OF VIRAL ANTIGEN CONTENT IN INACTIVATED ALUMINUM HYDROXIDE ADJUVANTED VACCINES", JOURNAL OF VIROLOGICAL METHODS, ELSEVIER BV, NL, vol. 25, no. 1, 1 January 1989 (1989-01-01), pages 101-108, XP001009902, ISSN: 0166-0934, DOI: 10.1016/0166-0934(89)90104-3
  • ZHU D ET AL: "Development of a Direct Alhydrogel Formulation Immunoassay (DAFIA)", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 344, no. 1, 15 May 2009 (2009-05-15), pages 73-78, XP026057801, ISSN: 0022-1759, DOI: 10.1016/J.JIM.2009.03.005 [retrieved on 2009-03-27]
  • ZHU D ET AL: "Use of o-phthalaldehyde assay to determine protein contents of Alhydrogel-based vaccines", VACCINE, ELSEVIER LTD, GB, vol. 27, no. 43, 9 October 2009 (2009-10-09), pages 6054-6059, XP026643905, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2009.07.067 [retrieved on 2009-08-04]
  • MARASKOVSKY EUGENE ET AL: "NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 10, no. 8, 15 April 2004 (2004-04-15) , pages 2879-2890, XP002615263, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-03-0245
  • Bernd: "In Deutschland zugelassene Impfstoffe mit Aluminium-Adjuvans", Acta Crystallographica Section A, 21 December 2009 (2009-12-21), XP055230010, Retrieved from the Internet: URL:http://www.bermibs.de/fileadmin/pdf/im pfen-sinn_oder_unsinn/impfstoffe_mit_alumi nium-adjuvans.pdf [retrieved on 2015-11-20]
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).